Biotech

Making “A Post-Pandemic World” — Jake Glanville

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 14:48:23 UTC.

Briefings

Jake Glanville, CEO of Centivax, interviews about developing a universal flu vaccine. The company aims to teach the immune system to recognize shared virus regions that resist mutation, potentially protecting against unseen strains without yearly reformulation. Glanville notes that seasonal flu vaccines have historically shown efficacy between 15% and 60%, and Centivax has tested the vaccine in 180 people before a Phase 2 trial. The interview covers immunology, vaccine design, and the business case for eradication, though the source material cuts off mid-sentence at 1:03:26.

Key points

• Centivax is a clinical-stage biotech company led by Jake Glanville, co-founder and CEO, developing a universal flu vaccine.
• The company has tested the vaccine in 180 people and is preparing for a Phase 2 trial to test its efficacy against mutated strains.

Context

The interview explores the technical challenges of creating a universal flu vaccine, contrasting it with the current seasonal approach. It highlights the historical struggle of flu vaccines to maintain efficacy due to viral mutation, with Glanville expressing hope that Centivax's approach could eventually lead to a pandemic-free future.

Limitations

The source evidence ends abruptly at timestamp 1:03:26, cutting off mid-sentence during the discussion of how to eradicate the flu. Specific details regarding the Phase 2 trial results, the company's current production capacity, and the specific business metrics are not provided in the available text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 15:12:55 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiftdaprfvr447dsyururwjydhjsmcymbew4biv6rkdopzlvj3fkb4